Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity by Shimon Slavin & Ralph W. Moss & Tibor Bakacs

Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity by Shimon Slavin & Ralph W. Moss & Tibor Bakacs

Author:Shimon Slavin & Ralph W. Moss & Tibor Bakacs
Format: pdf
Tags: Ipilimumab, CTLA-4 blockade, Anti-cancer immunotherapy, Graft-vs.-leukemia (GVL) effects, Graft-vs.-malignancy (GVM) effects, Autologous and allogeneic graft-vs.-host disease (GVHD), Minimal residual disease (MRD), Autoimmunity, Self and alloreactive T cells, Homeostatic proliferation
Publisher: Elsevier Ltd
Published: 2013-11-16T03:33:36+00:00


Download



Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.